The BALANCE Model for GLP-1s: what it is and where it stands
The short answer
The BALANCE Model for GLP-1s is a voluntary CMS Innovation Center model in which CMS negotiates GLP-1 prices and coverage terms for state Medicaid agencies and Medicare Part D plans. It began May 1, 2026 for participating states and runs through December 2031. CMS's page refers to it not launching in Medicare in 2027. The Medicare GLP-1 Bridge continues through December 31, 2027.
Key takeaways
- If you're on Medicare and want a GLP-1 for weight management, BALANCE doesn't apply to you in 2026 or 2027.
- If you're on Medicaid, ask your state agency or managed care plan whether your state joined.
- Joining is voluntary, and CMS says the model doesn't guarantee coverage for any individual.
- For Zepbound, only the KwikPen is on the BALANCE list. Vials and single-dose pens aren't.
- CMS hasn't said what Medicare coverage will exist after the Bridge ends on December 31, 2027.
The BALANCE Model is the federal government’s longer-term plan for GLP-1 access in Medicaid and Medicare. You’ll find confident summaries of it that are out of date, because the Medicare timeline changed after the announcement. This page gives the status the way the documents from CMS, the federal agency that runs Medicare, state it, with dates. It’s part of our Medicare and GLP-1 guide.
What BALANCE is
BALANCE stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. It’s a model run by the CMS Innovation Center. CMS describes its aim as increasing access to select GLP-1 medications and healthy lifestyle interventions, to help people with Medicare and Medicaid improve their health.
It works through negotiation. As part of the model, CMS negotiates drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of two groups: state Medicaid agencies and Medicare Part D plan sponsors.
Participation is voluntary for everyone involved: manufacturers, state Medicaid agencies and Part D plans. That’s the key to understanding where it stands. Nothing in BALANCE happens for a patient unless the manufacturer, and then the state or plan, has opted in.
Why it exists
CMS’s own framing is that GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health. It also says the drugs are expensive, and that Medicare and Medicaid generally don’t cover them for the weight loss indication. In Medicare, that gap comes from the Part D statute, which excludes agents when used for weight loss. In Medicaid, covering those drugs is optional for states.
Timeline
December 23, 2025: announcement. CMS announced BALANCE and said it would launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027. It said more information on state and plan participation would follow in early 2026.
March 9, 2026: negotiations completed, applications open. CMS said it had successfully completed negotiations with manufacturers Eli Lilly and Novo Nordisk, and that state Medicaid agencies and Part D plan sponsors could now apply. The request for applications for states, published the same day, says the model is tested from May 1, 2026 for participating states and January 1, 2027 for participating Part D sponsors, and runs through December 2031.
April 30, 2026: target date for the Medicare decision. The Part D application document set a condition, described below, and a target date of April 30, 2026 for CMS to notify manufacturers and plan sponsors of the outcome.
May 1, 2026: start of the model period for participating states. State Medicaid agencies can join from May 2026 through January 1, 2027.
July 31, 2026: state application deadline. A state had to respond to the request for applications by this date and sign a State Agreement with CMS by January 1, 2027.
CMS’s stated position on Medicare. CMS’s BALANCE page refers to the BALANCE Model not launching in Medicare in 2027 and says the Medicare GLP-1 Bridge will be extended through December 31, 2027.
December 2031: end of the model period.
The Medicare side: why it is not launching in 2027
The Part D application document explained the risk CMS was trying to manage. If only some plans covered GLP-1s for weight management, people who wanted the drugs would concentrate in those plans, a problem called adverse selection. So CMS wrote in a threshold: it would move forward in Medicare only if a critical mass of Part D plan sponsors opted in. If the plans applying covered less than 80% of the relevant Part D enrollment, CMS wouldn’t implement BALANCE in Medicare in 2027.
CMS’s page speaks of BALANCE not launching in Medicare in 2027.
What CMS does say is what replaces it. The Medicare GLP-1 Bridge is extended through December 31, 2027, which gives eligible Part D beneficiaries access to certain GLP-1 drugs and lets CMS collect more data on GLP-1 use to share with Part D plan sponsors “ahead of potential implementation of BALANCE in Part D.” A later Medicare launch is a possibility CMS has left open, not a commitment with a date.
What the Medicare design would have looked like
The application document shows what was planned for 2027. It’s useful mainly as a guide to what a future version might look like:
- CMS would have waived the Part D coverage exclusion for drugs used for weight loss for participating plans.
- In enhanced alternative plans and employer group waiver plans, no covered patient in the initial coverage phase would pay more than $50 per 28- or 30-day supply of a model drug from an in-network pharmacy.
- In actuarially equivalent and basic alternative plans, the limit was $125 per 28- or 30-day supply.
None of that is in effect. If you have Medicare, your route for weight management through December 31, 2027 is the Bridge, explained in full on the Bridge page.
The Medicaid side
For Medicaid, the model period began on May 1, 2026 for participating states. The model is open to all states, the District of Columbia and US territories that take part in the Medicaid Drug Rebate Program.
A participating state takes on the negotiated coverage terms. Its prior authorization criteria (the rules for the plan’s approval before it pays) must be no more burdensome than the negotiated criteria. They must not include step therapy stricter than the drug’s FDA-approved label or step therapy tied to lifestyle requirements. And they must be for FDA-approved indications only. A state can choose less restrictive criteria if they stay within the FDA-approved label.
If you receive a GLP-1 for weight management under the model in Medicaid, you get access to a lifestyle support program, provided by the manufacturer at no cost.
CMS is plain about the limits. Coverage in Medicaid depends on manufacturers and states taking part, patients are subject to the negotiated qualifications, and the model doesn’t guarantee coverage for any individual. The Medicaid coverage page explains how to check yours.
Which drugs are included
CMS lists all formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo. They’re included for indications (approved uses) that are already covered, with type 2 diabetes given as the example, and for weight management indications.
Two details stand out. The list is wider than the Bridge’s, which covers only Foundayo, Wegovy and the Zepbound KwikPen. And Zepbound appears in its KwikPen form only, as it does on the Bridge.
What this means for you
- On Medicare, wanting a GLP-1 for weight management: BALANCE doesn’t apply to you in 2026 or 2027. Check the Bridge criteria with the eligibility checker.
- On Medicare, with type 2 diabetes or another Part D covered indication: your Part D plan is the route, as it was before. See Part D costs in 2026.
- On Medicaid: ask your state Medicaid agency or managed care plan whether the state has joined BALANCE and what its criteria are.
- Planning for 2028 and later: CMS hasn’t said what Medicare coverage will exist after the Bridge ends on December 31, 2027. Anyone who tells you otherwise is guessing.
The Medicare and GLP-1 guide sets out the routes that exist in the meantime.
Frequently asked questions
What does BALANCE stand for?
Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. It's a CMS Innovation Center model that aims to increase access to select GLP-1 medications and healthy lifestyle interventions for people with Medicare and Medicaid. CMS negotiates drug pricing and coverage terms with GLP-1 manufacturers on behalf of state Medicaid agencies and Medicare Part D plan sponsors.
Is the BALANCE Model active in Medicare?
Not in 2027. CMS's BALANCE page refers to the model not launching in Medicare in 2027. In its place, the Medicare GLP-1 Bridge has been extended through December 31, 2027. CMS describes a later Part D launch only as a potential implementation, so it isn't confirmed.
Which drugs are in the BALANCE Model?
CMS lists all formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo. They're included for uses that are already covered, such as type 2 diabetes, and for weight management uses. Zepbound single-dose vials and single-dose pens aren't on the list.
Does BALANCE guarantee Medicaid coverage of GLP-1s?
No. CMS says coverage in Medicaid will depend on drug manufacturers and states taking part, that patients would be subject to qualifications set in the negotiations, including certain prior authorization requirements, and that the model will not guarantee coverage for any individual. Whether it reaches you depends on whether your state joined.
How is BALANCE different from the Medicare GLP-1 Bridge?
The Bridge is a short-term demonstration that operates outside Part D and charges eligible enrollees a $50 copay. BALANCE is a longer model, through December 2031, designed to work through participating state Medicaid programs and participating Part D plans. The Bridge was extended because BALANCE isn't launching in Medicare in 2027.
Sources (15)
- 1.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“The BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, aims to increase access to select glucagon‐like peptide‐1 (GLP-1) medications and healthy lifestyle interventions — to help people with Medicare and Medicaid improve their health. As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors.”
- 2.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“Participation in BALANCE is voluntary for manufacturers, state Medicaid agencies, and Part D plans.”
- 3.CMS: CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines, Promote Healthier Living
“Participation will be voluntary for manufacturers, states, and plans. Additional information will be released in early 2026 regarding state and Part D plan participation. The BALANCE Model will launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027.”
- 4.CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, State Medicaid Agency
“The CMS Innovation Center is testing this model beginning on May 1, 2026, for participating States and January 1, 2027, for participating Part D sponsors. The model will run through December 2031.”
- 5.CMS: Innovation Insight: Affordability of GLP-1s Takes Next Step with BALANCE Model RFAs
“CMS has successfully completed negotiations with manufacturers Eli Lilly and Novo Nordisk, a significant milestone in carrying out the BALANCE model, and State Medicaid Agencies and Part D plan sponsors can now apply to participate in BALANCE, another critical step to making GLP-1s more affordable and available to people with Medicare Part D and Medicaid.”
- 6.CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, Part D Plan Sponsors
“To address concerns of adverse selection, CMS will only move forward with implementation of the BALANCE Model with respect to Medicare if a critical mass of Part D plan sponsors opt to participate. [...] If this resulting quotient is below 80%, CMS will not move forward with implementation of the BALANCE Model in 2027 in Medicare. CMS will notify all participating manufacturers and plan sponsors as soon as practicable, with a target date of April 30, 2026.”
- 7.CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, Part D Plan Sponsors
“CMS is waiving the coverage exclusion for drugs used for weight loss within the definition of a covered Part D drug at section 1860D-2(e)(2)(A) of the Act for participating plans. [...] Participating Part D plan sponsors must ensure that no covered patient in an participating EA plan or EGWP, while in the initial coverage phase of the Part D benefit, pays more than $50 per 28- or 30-day supply in total out-of-pocket costs (including co-pay, co-insurance, or other direct costs) to receive any model drug listed in Appendix C from an in-network pharmacy. [...] Participating Part D plan sponsors must ensure that no covered patient in an AE or BA plan, while in the initial coverage phase of the Part D benefit, pays more than $125 per 28- or 30-day supply in total out-of-pocket costs to receive any model drug listed in Appendix C from an in-network pharmacy.”
- 8.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“Will the Medicare GLP-1 Bridge continue into 2027? Yes. The Medicare GLP-1 Bridge has been extended through December 31, 2027. [...] What is the impact of the BALANCE Model not launching in Medicare in 2027 on the Medicare GLP-1 Bridge? The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.”
- 9.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“All formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy®, the KwikPen formulation of Zepbound®, and Foundayo™. These are included for both currently covered indications (ex: type 2 diabetes) as well as weight management indications.”
- 10.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“State Medicaid agencies can join the model beginning in May 2026 through January 1, 2027. [...] Coverage in the Medicaid program will depend on participation by drug manufacturers and states. Patients would be subject to qualifications set by the negotiations between CMS and participating manufacturers, including certain prior authorization requirements. Therefore, this model will not guarantee coverage for any individual.”
- 11.CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, State Medicaid Agency
“Model participation is open to all states, the District of Columbia, and all U.S. territories that participate in the Medicaid Drug Rebate Program (MDRP). [...] States will participate in the model by responding to this state RFA by no later than July 31, 2026, and executing a SA with CMS by January 1, 2027.”
- 12.CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, State Medicaid Agency
“The prior authorization criteria applied must be: (i) no more burdensome than the criteria listed in Section 2.7.3; (ii) without step therapy that is more burdensome than the applicable model drug’s FDA-approved label (and no such step therapy or utilization may include step therapy related to lifestyle or similar requirements); and (iii) for FDA-approved indications only. [...] The participating state may choose to adopt Coverage Criteria that are less restrictive at their discretion, provided the criteria remain within the FDA approved label.”
- 13.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“All beneficiaries receiving GLP-1s for weight management under the BALANCE model in Medicaid will be provided with access to a lifestyle support program, provided by the manufacturer at no cost.”
- 14.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 15.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
